Organisation paid for research Program year 2025 Source: CMS Open Payments

American Oncology Partners

Neither a doctor nor a teaching hospital

Research payments

$317,988

30 payments

Through program year 2025, American Oncology Partners is reported as receiving $317,988 in research payments, across 30 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $151,501 8
2023 Research $10,753 3
2022 Research $28,202 7
2021 Research $112,732 11
2020 Research $14,800 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. Genentech, Inc. $155,539 18 payments
  2. Janssen Research & Development, LLC $108,112 5 payments
  3. Mirati Therapeutics, Inc. $22,630 1 payment
  4. GlaxoSmithKline, LLC. $20,759 2 payments
  5. BeiGene USA, Inc. $5,753 2 payments
  6. CTI BioPharma Corp. $5,195 2 payments
Studies the money was for Research payments · program years 2020–2025
  1. Atezolizumab Cabozantinib VS Docetaxel in Metastatic Nsclc Previously Treated With Cpi Chemo $81,130 12 payments
  2. CLL 1L Fit GV FCR Br $74,409 6 payments
  3. Investigation-specific Appendix 3 to Master Protocol PLATFORMPANSC2001 (KALEIDOSCOPE) A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer $38,750 2 payments
  4. A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan $33,500 1 payment
  5. A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc $29,500 1 payment
  6. A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation $22,630 1 payment
  7. A Randomized, Multicenter, Double-Blind, Phase 3 Study to Investigate $20,759 2 payments
  8. A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer $6,362 1 payment
  9. A Phase 3 Randomized, Open-Label Study of Zanubrutinib (BGB-3111) Plus Rituximab Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma $5,753 2 payments
  10. PACIFICA Phase 3 $5,195 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record